Welcome to our dedicated page for Royalty Pharma Plc SEC filings (Ticker: RPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Royalty Pharma plc (Nasdaq: RPRX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its royalty-based business model, capital structure and portfolio performance. As a company incorporated in England and Wales with Class A ordinary shares listed on The Nasdaq Stock Market LLC under the symbol RPRX, its SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with registration statements and indenture-related documents.
In its filings, Royalty Pharma explains how it acquires and manages royalty interests on biopharmaceutical products and defines key metrics such as Portfolio Receipts, royalty receipts, milestones and other contractual receipts. The company also discloses non-GAAP liquidity measures, including Adjusted EBITDA, ROIC Adjusted EBITDA, Portfolio Cash Flow and ROIE Portfolio Cash Flow, and reconciles these to net cash provided by operating activities. Debt-related filings describe senior unsecured notes issued under an indenture among Royalty Pharma plc, Royalty Pharma Holdings Ltd, Royalty Pharma Manager, LLC and Wilmington Trust, National Association, as trustee, including coupon rates, maturities, guarantees and covenant terms.
Form 8-K current reports highlight material events such as quarterly earnings releases, debt offerings, changes in directors and other significant corporate developments. These filings can be used to track Royalty Pharma’s capital deployment into new royalty transactions, updates to its share repurchase program, dividend decisions and other actions affecting shareholders.
On Stock Titan’s SEC filings page for RPRX, users can access Royalty Pharma’s latest 10-K, 10-Q and 8-K filings as they are posted to EDGAR. AI-powered summaries help explain complex sections, such as the description of Portfolio Receipts, non-GAAP liquidity measures, and indenture provisions for senior notes, allowing readers to quickly understand the implications of lengthy documents. The page also surfaces Form 4 insider transaction reports, so users can review trading activity by directors and officers alongside the company’s broader disclosure record.
Royalty Pharma plc EVP & CFO Terrance P. Coyne, through affiliated entities, reported planned open-market sales of Class A Ordinary Shares. On April 1, 2026, TPC RP EPA1 LLC sold 1,875 shares and TPC RP 2021, LLC sold 32,916 shares at a weighted average price of $48.3318 per share, all under a Rule 10b5-1 trading plan adopted on August 8, 2025. After these sales, TPC RP EPA1 LLC held 42,011 shares and TPC RP 2021, LLC held 32,916 shares. Additional holdings reported include 24,170 shares in a spouse’s IRA, 23,270 shares in an IRA, 1,500 shares held directly, and 1,450 shares held by a spouse, indicating that the transactions represent a partial reduction of a larger overall position.
TPC RP EPA1 LLC and TPC RP 2021 LLC reported multiple sales of Common Stock under Form 144. The filings list numerous dispositions between 01/02/2026 and 03/23/2026, including large line items such as 108,759 shares sold on 02/03/2026 and 69,665 shares sold on 02/02/2026. The entries show per-transaction share amounts and gross proceeds for each sale.
Bassler Bonnie L reported acquisition or exercise transactions in this Form 4 filing.
Royalty Pharma plc director Bonnie L. Bassler received an equity grant of 815 Class A Ordinary Shares. The award was made on a grant/award basis at a reference price of $45.977 per share and was issued under the company’s 2020 Independent Director Equity Incentive Plan in lieu of a $37,500 quarterly retainer payment. Following this grant, Bassler directly holds 73,947 Class A Ordinary Shares.
Royalty Pharma plc reported that entities associated with EVP & CFO Terrance P. Coyne sold Class A Ordinary Shares of the company. On March 23, 2026, TPC RP 2021, LLC sold 32,916 shares and TPC RP EPA1 LLC sold 1,875 shares in open-market transactions at a weighted average price of $45.5287 per share, with individual prices ranging from $45.30 to $45.94.
All reported transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025. After these sales, TPC RP 2021, LLC held 65,832 shares and TPC RP EPA1 LLC held 43,886 shares, and Coyne also reported additional indirect and direct holdings through various IRA and family accounts.
RPRX affiliates reported multiple Rule 144 sales of Common Stock. The excerpt lists numerous dispositions by two related holders, TPC RP EPA1 LLC and TPC RP 2021 LLC, across January–March 2026. Examples include sales of 1,875 and 32,916 shares by those entities, respectively.
Reporting persons filed Form 144 reporting proposed and completed sales of Common Stock of RPRX. The excerpt lists multiple transactions by related entities, including sales on 12/17/2025, 01/07/2026, and 03/18/2026, with individual trade sizes such as 79,346, 123,965, and 100,462 shares respectively. Examples shown include sales by GWL 2014 G LLC (79,346 shares on 12/17/2025) and George Lloyd IRA (136,980 shares on 03/04/2026). The filing records gross proceeds for each sale in U.S. dollars alongside the share counts.
RPRX submitted a Form 144 reporting a proposed sale of 100,462 shares of Common Stock acquired on 06/20/2020.
The filing lists the broker Goldman Sachs & Co. LLC and records multiple sales by affiliated entities over the prior three months, including transactions dated 01/07/2026, 01/21/2026, and 03/04/2026 with share amounts and gross proceeds documented in the filing.
Royalty Pharma plc executive vice president and CFO Terrance P. Coyne reported indirect open-market sales of a total of 34,791 Class A ordinary shares of Royalty Pharma plc on March 2, 2026. The sales were made by entities TPC RP 2021, LLC and TPC RP EPA1 LLC at weighted average prices around $46.67 and $47.01 per share, in multiple transactions within disclosed price ranges. All reported transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025.
Repare Therapeutics related entities reported multiple sales of common stock under a Form 144. The excerpt lists transactions by GWL 2013 NG LLC and GWL 2014 G LLC on several dates in December 2025 through February 2026.
Examples shown include 123,965 shares sold on 01/21/2026 and 110,000 shares sold on 12/03/2025. The filing records dollar proceeds for each sale in the excerpt.
TPC RP EPA1 LLC and TPC RP 2021 LLC reported multiple sales of Common Stock. The excerpt lists discrete market sales on several dates in 12/2025–02/2026, including transactions such as 108,759 shares for $4,659,572.71 on 02/03/2026 and 69,665 shares for $2,938,636.90 on 02/02/2026.
The filings show repeated, scheduled dispositions by affiliated entities rather than a single block sale; cash‑flow recipients are the named selling entities. Transaction timing and per‑trade amounts are shown inline with each sale record.